Know Cancer

or
forgot password

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI


N/A
18 Years
N/A
Not Enrolling
Both
Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer

Thank you

Trial Information

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI


Inclusion Criteria:

- Measurable disease by RECIST criteria

- Pathologic diagnosis of renal cell cancer

- Advanced (stage IV) renal cell cancer

- Karnofsky performance status of (KPS>70)

- Consent to participate in the clinical trial

Exclusion Criteria:- Patients who cannot complete a PET/CT scan.

- Pregnant women.

- Healthy volunteers.

- Patients participating in other research protocols will be excluded from this study.

- Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications
for MRI.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

histopathology

Outcome Time Frame:

clinical outcome usually prior to beginning on the trial

Safety Issue:

No

Principal Investigator

Dr Andrew Quon

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

RENAL0013

NCT ID:

NCT00537056

Start Date:

October 2007

Completion Date:

April 2012

Related Keywords:

  • Kidney Neoplasms
  • Carcinoma, Renal Cell
  • Kidney (Renal Cell) Cancer
  • Neoplasms
  • Carcinoma
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

Name

Location
Stanford University School of Medicine Stanford, California  94305-5317